Age Affects the Mitigating Efficacy of Riboflavin Against Cisplatin-Induced Toxicity In Vivo

References

• Ali BH, Al-Moundhri M, Tageldin, M, Al Husseini IS, Mansour MA, et al.: Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 46, 3355–3359, 2008.
   PubMed Web of Science ®Google Scholar
• Suo Z, Lippard SJ, and Johnson KA: Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization. Biochemistry 38(2), 715–726, 1999.
   PubMed Web of Science ®Google Scholar
• Chirino YI, and Pedraza-Chaverri J: Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61(3), 223–242, 2009.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, et al.: Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48(3), 457–467, 2010.
   PubMed Web of Science ®Google Scholar
• Baier J, Maisch T, Maier M, Engel E, Landthaler M, et al.: Singlet oxygen generation by UVA light exposure of endogenous photosensitizers. Biophys J 91(4), 1452–1459, 2006.
   PubMed Web of Science ®Google Scholar
• Khan YA, Kashiwabuchi RT, Martins SA, Castro-Combs JM, Kalyani S, et al.: Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases. Ophthalmology 118(2), 324–331, 2011.
   PubMed Web of Science ®Google Scholar
• Munoz MA, Pacheco A, Becker MI, Silva E, Ebensperger R, et al.: Different cell death mechanisms are induced byhydrophobic flavin in human tumor cells after visible light irradiation. J Photochem Photobiol B 103(1), 57–67, 2011.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wentworth P, Kyle RA, Lerner RA, and Wilson IA: Cofactor-containing antibodies: crystal structure of the original yellow antibody. Proc Natl Acad Sci U S A 103(10), 3581–3585, 2006.
   PubMed Web of Science ®Google Scholar
• Webster RP, Gawde MD, and Bhattacharya RK: Modulation of carcinogen induced DNA damage and repair enzyme activity by dietary riboflavin. Cancer Lett 98, 129–135, 1996.
   PubMed Web of Science ®Google Scholar
• Hassan I, Chibber S, and Naseem I: Ameliorative effect of riboflavin on the cisplatin induced nephrotoxicity and hepatotoxicity under photoillumination. Food Chem Toxicol 48(8–9), 2052–2058, 2010.
   PubMed Web of Science ®Google Scholar
• Hassan I, Chibber S, Khan AA, and Naseem I: Riboflavin ameliorates cisplatin induced toxicities under photoillumination. Plos One 7(5), e36273, 2012. doi: 10.1371/journal.pone.0036273.
   PubMedGoogle Scholar
• Husain E, and Naseem I: Riboflavin-mediated cellular photoinhibition of cisplatin-induced oxidative DNA breakage in mice epidermal keratinocytes. Photodermatol Photoimmunol Photomed 24(6), 301–307, 2008.
   PubMed Web of Science ®Google Scholar
• Edwards AM, Silva E, Jofre B, Becker MI, and De Ioannes AE: Visible light effects on tumoral cells in a culture medium enriched with tryptophan and riboflavin. J Photochem Photobiol B 24(3), 179–186, 1994.
   PubMed Web of Science ®Google Scholar
• de Souza AC, Kodach L, Gadelha FR, Bos CL, Cavagis AD, et al.: A promising action of riboflavin as a mediator of leukaemia cell death. Apoptosis 11(10), 1761–1771, 2006.
   PubMed Web of Science ®Google Scholar
• de Souza QKC, Zambuzzi WF, Santos de Souza AC, da Silva RA, Machado D, et al.: A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours. Cancer Lett 258(1), 126–134, 2007.
   PubMed Web of Science ®Google Scholar
• Singh S, Parulekar W, Murray N, Feld R, Evans WK, et al.: Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23, 850–856, 2005.
   PubMed Web of Science ®Google Scholar
• Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, et al.: Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer 21(2), 565–573, 2013.
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, and Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27), 2061–2067, 1999.
   PubMed Web of Science ®Google Scholar
• Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, et al.: Age-related differences in susceptibility to cisplatin-induced renal toxicity. J Appl Toxicol 30(2), 172–182, 2010.
   PubMed Web of Science ®Google Scholar
• Tachibana A, Nagasawa A, Kitamura A, Miyazaki S, and Murase K: Experimental verifi cation of age-dependent cisplatin-induced nephrotoxicity in rats using dynamic contrast-enhanced computed tomography. Jpn J Radiol 28, 123–131, 2010.
   PubMed Web of Science ®Google Scholar
• Andziak B, and Buffenstein R: Disparate patterns of age-related changes in lipid peroxidation in long-lived naked mole-rats and shorter-lived mice. Aging Cell 5(6), 525–532, 2006.
   PubMed Web of Science ®Google Scholar
• Sverko V, Sobocanec S, Balog T, and Marotti T: Age and gender differences in antioxidant enzyme activity: potential relationship to liver carcinogenesis in male mice. Biogerontology 5(4), 235–242, 2004
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, et al.: Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4), e148–e160, 2012. doi: 10.1016/S1470-2045(11)70383-7.
   PubMed Web of Science ®Google Scholar
• Pepe C, Hasan B, Winton TL, Seymour L, Graham B, et al.: Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25(12), 1553–1561, 2007.
   PubMed Web of Science ®Google Scholar
• Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, et al.: Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 26(21), 3573–3581, 2008.
   PubMed Web of Science ®Google Scholar
• Naseem I, Hassan I, Alhazza IM, and Chibber S: Protective effect of riboflavin on cisplatin induced toxicities: a gender-dependent study. J Trace Elem Med Biol 29, 303–314, 2015.
   PubMed Web of Science ®Google Scholar
• Marklund S, and Marklund G: Involvement of superoxide anion radical in the auto oxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47, 469–474, 1974.
   PubMedGoogle Scholar
• Aebi H: Catalase in vitro. Meth Enzymol 105, 121–126, 1984.
   PubMed Web of Science ®Google Scholar
• Habig WH, Pabst MJ, and Jokoby WB: Glutathione S-transferase: the first enzymatic step in mercapturic acid formation. J Biol Chem 249(22), 7130–7139, 1974.
   PubMed Web of Science ®Google Scholar
• Buege JA, and Aust SD: Microsomal lipid peroxidation. Meth Enzymol 52, 302–310, 1978.
   PubMedGoogle Scholar
• Levine RL, Williams J, Stadman ER, and Shacter E: Carbonyl assay for determination of oxidatively modified proteins. Meth Enzymol 233, 346–357, 1994.
   PubMed Web of Science ®Google Scholar
• Jollow DJ, Mitchell JR, Zampaglione N, and Gillette JR: Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzene oxide as hepatotoxic metabolite. Pharmacology 11, 151–169, 1974.
   PubMed Web of Science ®Google Scholar
• Sedlak J, and Lindsay RH: Estimation of total, protein-bound and non-protein sulfhydryl groups in tissues with Ellman's reagent. Anal Biochem 25, 192–205, 1968.
   PubMed Web of Science ®Google Scholar
• Singh NP, McCoy MT, Tice RR, and Schneider EL: A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 175, 184–191, 1988.
   PubMed Web of Science ®Google Scholar
• Hassan I, Chibber S, and Naseem I: Vitamin B2: a promising adjuvant in cisplatin based chemoradiotherapy by cellular redox management. Food Chem Toxicol 59, 715–123, 2013.
   PubMed Web of Science ®Google Scholar
• Mathe C, Bohacs A, Duffek L, Lukacsovits J, Komlosi ZI, et al.: Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J 37(4), 888–894, 2011.
   PubMed Web of Science ®Google Scholar
• Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, et al.: Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 28(12), 2038–2045, 2010.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Van Calster B, van de Poll-Franse LV, Hendrickx W, Røislien J, et al.: Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol 27(18), 2931–2937, 2009.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Jr Hellman S, and Rosenberg SA, eds.: Cancer Principles and Practice of Oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997.
   Google Scholar
• Hudson MM, Link MP, and Simone JV: Milestones in the curability of pediatric cancers. J Clin Oncol 32(23), 2391–2397, 2014.
   PubMed Web of Science ®Google Scholar
• Duggin K, Tickle K, Norman G, Yang J, Wang C, et al.: Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors. J Pediatr Oncol Nurs 31(5), 277–283, 2014.
   PubMed Web of Science ®Google Scholar
• Chang JE, Medlin SC, Kahl BS,Longo WL, Williams EC, et al.: Augmented and standard Berlin-Frankfurt-Münster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymph 49(12), 2298–2307, 2008.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, and Pavlidis N: Juvenile cancer: improving care for adolescents and young adults within the frame of medical oncology. Ann Oncol 16(2), 181–188, 2005.
   PubMed Web of Science ®Google Scholar
• Chirtes F, and Albu S: Prevention and restoration of hearing loss associated with the use of cisplatin. BioMed Res Int, 2014, 1–9, 2014. doi:10.1155/2014/925485
   Google Scholar
• Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, et al.: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94(3), 173–181, 2002.
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, and Reeves WB: Mechanisms of cisplatin nephrotoxicity. Toxins 2(11), 2490–2518, 2010.
   PubMed Web of Science ®Google Scholar
• Townsend DM, Tew KD, He L, King JB, and Hanigan MH: Role of glutathione S-transferase Pi in cisplatin induced nephrotoxicity. Biomed Pharmacother 63(2), 79–85, 2009.
   PubMed Web of Science ®Google Scholar
• Pandey KB, and Rizvi SI: Markers of oxidative stress in erythrocytes and plasma during aging in humans. Oxid Med Cell Longev 3(1), 2–12, 2010.
   PubMed Web of Science ®Google Scholar
• Kenneth AC: Chemotherapy–associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3, 294–300, 2004.
   PubMedGoogle Scholar
• Kasapoglu M, and Ozben T: Alteration of antioxidant enzymes and oxidative stress markers in aging. Exp Gerontol 36, 209–220, 2001.
   PubMed Web of Science ®Google Scholar
• Fleck C, Kretzschel I, Sperschneider T, and Appenroth D: Renal amino acid transport in immature and adult rats during chromate and cisplatinum-induced nephrotoxicity. Amino Acids 20, 201–215, 2001.
   PubMed Web of Science ®Google Scholar
• Appenroth D, Winnefield K, and Braunlich H: Nephrotoxicity and pharmacokinetics of cisplatinum in young and adult rats. Biomed Biochem Acta 47, 791–797, 1988.
   PubMedGoogle Scholar
• Higami Y, Shimokawa I, Okimoto T, and Ikeda T: An age related increase in the basal level of DNA damage and DNA vulnerability to oxygen radicals in the individual hepatocytes in male F344 rats. Mutat Res 316, 59–67, 1994.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Takasaki W, Sato I, and Tsuda S: DNA damage measured by comet assay and 8-OH-dG formation related to blood chemical analyses in aged rats. J Toxicol Sci 32, 249–259, 2007.
   PubMedGoogle Scholar
• Salman M, Naseem I, Hassan I, Khan AA, and Alhazza IM: Riboflavin arrests cisplatin-induced neurotoxicity by ameliorating cellular damage in dorsal root ganglion cells. BioMed Res Int. 2015, Article ID 603543, 5pp., 2015. doi:10.1155/2015/603543
   Web of Science ®Google Scholar
• Salman M, and Naseem I: Riboflavin as adjuvant with cisplatin: study in mouse skin cancer model. Front Biosci (Elite Ed.) 7, 278–291, 2015.
   Google Scholar